Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks
... for infections of
the respiratory tract in cystic fibrosis
patients has received a second
orphan drug ... can cause lethal infections in cystic fibrosis
patients. For Axentis
Pharma AG of Zurich, ... B. cepacia infections
still occur in cystic fibrosis
patients and can lead to fatal sepsis. The
Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)
... JUNCTION, N.J., June 25 /PRNewswire/ -- Cystic fibrosis
Foundation Therapeutics Inc., the nonprofit affiliate of the Cystic fibrosis
Foundation, has provided a $2.2 million award to ... to treat Pseudomonas lung infections in cystic fibrosis
(CF) and non-CF bronchiectasis patients. ...
New Legislation Seeks to Boost Participation in Clinical Trials for Rare Diseases
... populations. This is particularly true for cystic fibrosis
(CF). More than 30 promising CF drugs are in ... more people with rare diseases - including cystic fibrosis
- to participate in clinical trials," said Robert J. Beall, Ph.D., president and CEO of the Cystic fibrosis
Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
... pirfenidone in patients with idiopathic pulmonary fibrosis
(IPF) were presented today in an oral ...
Idiopathic pulmonary fibrosis
(IPF) is a disabling and ultimately fatal disease ... portfolio addressing idiopathic pulmonary fibrosis
(IPF) and hepatitis C virus (HCV) infections. ...
Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
... and reduce the incidence of subretinal fibrosis
without obvious side effects to the retina," says ... vitreoretinopathy (PVR) and subretinal fibrosis
(scarring). When the retina becomes separated ... space between the retina and the RPE, subretinal fibrosis
is the result and can prevent the recovery of ...
Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial
... the leading cause of death for people
with cystic fibrosis
and this deterioration now averages 1-2% per ... formulation to publish positive results in
it promises convenience for patients who have ... authorisation for Bronchitol for treating
in Europe and elsewhere. Pharmaxis will now move ...
Cystic Fibrosis - Orphan Drug Designation for Innovative Treatment Against Lung Infections by Axentis Pharma AG
infections of the respiratory tract in cystic fibrosis
patients has received
orphan drug designation in ... of the respiratory tract in patients
with cystic fibrosis
that is delivered directly to the site of ... a clinical stage
treatment against cystic fibrosis
About Fluidosome technology
Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis
... for Bronchitol for treating cystic fibrosis
in Europe and elsewhere.
The results of ... landscape for people living with cystic fibrosis
and provide a
new therapeutic regimen that helps ... pharmaceutical markets are affected with cystic fibrosis
and no products
have been approved to improve ...
FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
... interferon treatment, significant bridging fibrosis
or cirrhosis, or HCV genotype 1 infection. It is ... interferon treatment, significant bridging fibrosis
or cirrhosis, or HCV genotype 1 infection.
... 2,293 adult patients with moderate-to-severe fibrosis
or cirrhosis who failed previous treatment with ...
Positive Data From Lung Study May Lead to First FDA Approved Treatment for Pulmonary Fibrosis
... -- The Coalition for Pulmonary fibrosis
(CPF) is calling this a historic time in the ... be saved," Shreve said.
About Pulmonary fibrosis
(PF) is a lung disorder characterized by a ...
PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
... in patients with nonsense mutation cystic fibrosis
(nmCF) in 2009.
The United States Adopted ... drug status for the treatment of DMD and cystic fibrosis
due to nonsense mutations. The FDA has also ... Center for Research Resources and the Cystic fibrosis
Foundation Therapeutics Inc. (the nonprofit ...
Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients
... with no
evidence of progression to collagen fibrosis
or chronic idiopathic
myelofibrosis. ... Reticulin Formation and Risk for Bone Marrow fibrosis
-- Nplate administration increases the ... to 10 mcg/kg.
-- Progression to marrow fibrosis
with cytopenias was not reported in ...
PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements in Chloride Channel Function in Cystic Fibrosis Patients
... chloride channel function of children with cystic fibrosis
caused by a particular genetic mutation, ... head of the
department of pediatrics and Cystic fibrosis
Center at Hadassah University
(Logo: ... Vice President of Medical Affairs at
the Cystic fibrosis
Foundation, on promising developments in CF ...
Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis
... eFlow Nebulizer System for use in cystic fibrosis
and chronic obstructive pulmonary disease ... are being presented at the
North American Cystic fibrosis
Conference (NACFC) and ICAAC/IDSA meetings
taking ... bacterial exacerbations in
patients with cystic fibrosis
and COPD. The company has also built a
PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
Commission for the treatment of cystic fibrosis
and DMD due to nonsense
mutations. The FDA has ... for Research Resources and
notably, the Cystic fibrosis
Foundation Therapeutics Inc. (the nonprofit
affiliate of the Cystic fibrosis
Foundation), which recently expanded
support of ...
Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections
... treatment of severe pulmonary
infection in cystic fibrosis
patients. The new formulation allows ... the
treatment of pulmonary infection in cystic fibrosis
patients. The product
ARB-CF0223 also known as ... to the endobronchial sites of
infection in cystic fibrosis
patients. This results in prolonged, high
Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins
clinical trial evaluating Bronchitol in cystic fibrosis
The Phase 3 trial is being conducted ... seeks approval to market Bronchitol for cystic fibrosis
Pharmaxis Chief Executive ... the FDA
and with assistance from the U.S. Cystic fibrosis
Foundation. This trial
follows the recent closure ...
Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment
... trial of Bronchitol for the treatment of cystic fibrosis
The first efficacy ... forward to the results helping to
shape cystic fibrosis
clinical practice in the future."
Pharmaxis has ... pharmaceutical markets are
affected with cystic fibrosis
and no products have been approved to ...
Bronchitol Cystic Fibrosis Dose Trial Results Positive
... in Lung Function of Cystic fibrosis
SYDNEY, Australia, Aug. 11 ... 40 mg of Bronchitol in 48 patients with cystic fibrosis
at 12 centres
across Canada and Argentina. ... flow) and the respiratory domain
of the cystic fibrosis
quality of life questionnaire (CFQR).
PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
... Therapy to Address an Underlying Cause of Cystic fibrosis
SOUTH PLAINFIELD, N.J. and BETHESDA, Md., ... -- PTC
Therapeutics, Inc. (PTC) and Cystic fibrosis
Foundation Therapeutics, Inc.
(CFFT), the nonprofit affiliate of the Cystic fibrosis
announced the expansion of an ...
The Ocean Becomes a Pipeline To A Cure for Cystic Fibrosis
... and quality
of life for people with cystic fibrosis
(CF), a fatal genetic disease that
causes the ... in Australia noticed young surfers with
had significantly healthier lungs. The doctors ... led the Southern
California Chapter of the Cystic fibrosis
Foundation to form a "PIPELINE TO
A CURE" ...
Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
... Data Presented at the European Cystic fibrosis
MONMOUTH JUNCTION, N.J., ... is being developed for the treatment of cystic fibrosis
patients who have lung infections due to the ... presented today at the 31st European Cystic fibrosis
Conference in Prague, Czech ...
PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
... - Data Presented at the 31st European Cystic fibrosis
SOUTH PLAINFIELD, N.J. and PRAGUE, ... new data from two
studies of PTC124 in cystic fibrosis
(CF). Results from an Israeli Phase 2a
extension ... CF."
About Cystic Fibrosis
(CF) is among the most common life-threatening ...
PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
... - Findings Show Cystic fibrosis
Patients Cough More Than 600 Times Per Day ... head of the Department of
Pediatrics and Cystic fibrosis
Center, Hadassah University Hospital.
"Chronic ... and children. Patients with CF
lack the cystic fibrosis
transmembrane conductance regulator ...
PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
... we have achieved to date
in DMD and cystic fibrosis
(CF) and constitutes a major step forward ... muscular dystrophy (DMD) and cystic fibrosis
It is estimated that 13% of the cases of ... the Muscular Dystrophy Association (MDA),
Foundation Therapeutics, Inc. (CFFT), Parent ...
InterMune Announces Progress on Pirfenidone in IPF
... pirfenidone in patients
with idiopathic pulmonary fibrosis
(IPF). The roll-over study will be open
to ... Pirfenidone
in Patients with Idiopathic Pulmonary fibrosis
in Japan" [Session C95], is
now posted at ... .
Idiopathic pulmonary fibrosis
(IPF) is a disabling and ultimately fatal
Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
... Md., March 27 /PRNewswire/ -- The Cystic fibrosis
announced today that VX-770, an oral ... philanthropy was wholly untested,
the Cystic fibrosis
Foundation was willing to take a chance that ... safety and efficacy of the compound.
is a life-threatening genetic disease that ...
PTC Therapeutics Announces Publication of Preclinical Data in PNAS
... and Restores Protein Function in Cystic fibrosis
SOUTH PLAINFIELD, N.J., Feb. 4 ... active in a preclinical model of cystic fibrosis
(CF). These results
support and add to research ... cases of most
inherited diseases, such as cystic fibrosis
(10%) and Hurler's syndrome
Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes
... key indicators of health for people with
-- including lung function and nutritional status ... the country, we are seeing great care for cystic fibrosis
even better," said Bruce C. Marshall, M.D., ... purposes.
About the Cystic fibrosis
Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
... of Utah research team, which found that
(CF) patients younger than age 18 did not survive ... than ever in referring children with cystic fibrosis
transplantation, with careful ... child's
illness," said Allen. He said that cystic fibrosis
centers must provide
appropriate social and ...
Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
... in chronic hepatitis C
nonresponder patients with fibrosis
or cirrhosis. The goal of maintenance
therapy in ... Alfa-2b Leads
to a Significant Reduction in fibrosis
and Inflammatory Score in Chronic
Hepatitis C Nonresponder Patients with fibrosis
or Cirrhosis; S. Kaiser, et
al., Abstract 1311, ...
PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
... Society meeting and North
American Cystic fibrosis
Conference, further support our belief that ... of longer-term studies in
DMD and cystic fibrosis
(CF) as well as additional proof of concept ... of PTC124 in nonsense-mutation-mediated cystic fibrosis
Duchenne muscular dystrophy (DMD). It ...
Man's Best Friend May Open Door to Understanding Fibrotic Lung Disease in Human and Animal Populations
... to Discuss
Joint Research Efforts Into Pulmonary fibrosis
and Other Fibrotic Lung
LAFAYETTE, ... that the
opportunity to study canine pulmonary fibrosis
may provide a new approach
that will lead to the ... About the Coalition for Pulmonary fibrosis
The Coalition for ...
Promising Cystic Fibrosis Compound on Track for Development
... Made Possible by Early Investment by Cystic fibrosis
... . About the Cystic fibrosis
Foundation The Cystic fibrosis
Foundation is the leading organization devoted ...
TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics
... to supply reagents for Osmetech's recently launched eSensor(R) Cystic fibrosis
Carrier Detection (CFCD) System and the eSensor(R) XT-8 System for ... platform and the eSensor(R) XT-8 platform, presently available for Cystic fibrosis
Carrier Detection and Warfarin Sensitivity testing, respectively. The ...
InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
... from its Phase 3
CAPACITY program of pirfenidone in idiopathic pulmonary fibrosis
to market open on Tuesday, February 3. InterMune will conduct ... has a research and development portfolio addressing idiopathic
(IPF) and hepatitis C virus (HCV) infections. The
pulmonology portfolio ...
Nanoemulsion Kills Highly Resistant Bacteria Found in Patients With Cystic Fibrosis
... also demonstrated bactericidal activity in the presence
of cystic fibrosis
sputum and against bacterial biofilms, protective coatings
that surround ... The company expects to initiate a phase 1 study in
humans with cystic fibrosis
NanoBio(R) Corp. is a privately held ...
Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy
... angiogenesis (new blood
vessel formation) when evaluated at 10 days, early fibrosis
connective tissue formation) when evaluated at 30 days and, in some cases,
when evaluated at 60 days. The treatment arms,
however, showed a tendency ...
Mpex Initiates a Phase 2 Clinical Trial of Aerosol MP-376 in the Treatment of Chronic Bacterial Infections in Cystic Fibrosis Patients
... 3 studies,
which we hope to initiate in 2009."
Patients with cystic fibrosis
(CF) suffer from chronic infections of
the lower respiratory tract that ... for the prevention of bacterial exacerbations in
patients with cystic fibrosis
and severe chronic bronchitis. The company
has also built a discovery and ...
Inspire's Phase 3 CF Trial, Using PARI's Nebulizer & Compressor, Shows Positive Top-Line Results
... LC STAR nebulizer and PRONEB Ultra compressor for the
treatment of cystic fibrosis
"We are pleased to see these positive top-line results and hope ... and
minimal medication waste.
Denufosol for the treatment of cystic fibrosis
has been granted Fast
Track designation and orphan drug status in the ...